Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plan B Decision Mobilizes House Members To Seek FDA Integrity Review

This article was originally published in The Tan Sheet

Executive Summary

A House bill directing FDA to conduct a formal review of the process leading up to its decision to designate as "not approvable" the Rx-to-OTC switch application for the Plan B emergency contraceptive was introduced by Rep. Carolyn Maloney (D-N.Y.) on May 14
Advertisement

Related Content

House Democrats Take Plan B Battle To Appropriations Bill
House Democrats Take Plan B Battle To Appropriations Bill
House Democrats Take Plan B Battle To Appropriations Bill
Plan B GAO Investigation Sought By House Members
Plan B GAO Investigation Sought By House Members
Plan B GAO Investigation Sought By House Members
Plan B OTC Submission Fails On Lack Of Data In Teens
Plan B OTC Submission Fails On Lack Of Data In Teens
Barr Adds Preven To OTC Contraceptive Pipeline
Plan B Behind-The-Counter Status Discouraged By Panel Members

Topics

Advertisement
UsernamePublicRestriction

Register

PS096837

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel